Aquestive Therapeutics (AQST) Q2 2025: Pre-Launch Spend Rises $4.2M as Anafilm Nears FDA Decision

August 12, 2025 | By EarningsIQ Research

Aquestive Therapeutics is entering the final stretch before its pivotal FDA decision on Anafilm, its oral epinephrine film, with pre-commercial investment accelerating and payer access strategies taking center stage. Management remains confident in the clinical and regulatory package, but rising launch costs and persistent payer hurdles signal a complex commercialization path. Investors should watch for financing clarity and FDA feedback as the company prepares for a first quarter 2026 launch.

Summary

• Payer Access Friction: Aquestive is building a patient-first access model to counter rising payer barriers and high deductibles.
• Launch Readiness Intensifies: Pre-commercial spend and advisory committee preparations accelerate as the FDA decision approaches.
• Financing and Execution Watch: Funding pathways and payer coverage will determine Anafilm’s initial commercial trajectory.

Performance Analysis

Revenue for the quarter reflected the transition from legacy products to new launches, with total revenues at $10 million, up 3% year-over-year when adjusting for a prior-year one-time deferred revenue event. Manufacture and supply revenue grew to $9.6 million, as gains from new collaborations and licensed products like UNDIF offset ongoing Suboxone decline. The base business, excluding one-time events, demonstrated resilience, especially in international markets.

Operating expenses rose sharply, driven by a $2 million increase in pre-launch commercial activities for Anafilm, alongside higher regulatory, personnel, and consulting costs. The company’s net loss widened to $13.5 million, reflecting the front-loaded investment needed for launch readiness. Cash on hand remains solid at $60.5 million, but management signaled the need for additional funding to fully support Anafilm’s commercialization. Non-GAAP adjusted EBITDA loss increased, consistent with the ramp in launch preparation spending.

• Pre-Launch Investment Spike: Selling, general, and administrative expenses climbed due to regulatory fees and Anafilm launch activities.
• Legacy Product Decline Offset: Growth in international and new licensed products helped counteract Suboxone erosion.
• Financing Needs Loom: Existing cash covers initial launch, but further funding is required for full-scale commercialization.

Overall, Aquestive is prioritizing Anafilm launch execution, with financial performance reflecting a deliberate shift of resources from legacy to growth assets.

Executive Commentary

Strategic Positioning

1. Anafilm Launch as Core Growth Driver

Aquestive’s business model is pivoting around Anafilm, an oral epinephrine film targeting severe allergic reactions. The product’s convenience and patient preference profile are expected to drive share shift from injectables and nasal sprays, supported by market research indicating strong favorability for oral administration. Management forecasts the rescue epinephrine market could double to $2 billion annually as innovation and awareness increase.

2. Patient-First Access and Payer Strategy

Recognizing payer barriers as a material headwind, Aquestive is developing a cash pay program to ensure immediate patient access at launch, regardless of insurance coverage obstacles. The company’s market access team brings deep expertise in pricing, contracting, and reimbursement, and is proactively engaging payers, though broad coverage will be a gradual process. Co-pay buy-downs and direct-to-patient support will be key levers in the near term.

3. Financing Flexibility and International Expansion

Management is actively pursuing multiple financing pathways, including EU-only rights out-licensing and alternative funding vehicles, to support Anafilm’s launch. The company is also preparing regulatory filings for Canada and the EU, aiming to broaden Anafilm’s addressable market and diversify revenue streams post-approval.

4. Operational Diversification and Supply Chain Stability

Manufacturing operations remain steady, with U.S.-based facilities insulated from current and proposed tariffs. Expansion into new collaborations and licensed products is helping offset legacy product declines and supporting operational leverage as Anafilm nears commercialization.

Key Considerations

This quarter marked a strategic inflection for Aquestive, as the company accelerated investment in Anafilm while managing legacy product headwinds and preparing for a complex payer environment.

Key Considerations:

• Launch Financing Pathways: Multiple proposals are under review, but the final capital structure will influence launch scale and speed.
• Payer Access Uncertainty: High deductibles and payer restrictions have delayed competitor uptake, highlighting the need for robust patient support and coverage strategies.
• Clinical Package Strength: Management and the CMO emphasized a comprehensive clinical program, including robust pediatric safety and efficacy data, positioning Anafilm favorably for regulatory review.
• Legacy-to-Growth Transition: International product growth and new collaborations are offsetting Suboxone erosion, but long-term upside hinges on Anafilm execution.

Risks

Material risks remain around payer access, as recent launches in the space have encountered significant coverage barriers and out-of-pocket costs for patients. Financing for a full-scale launch is not yet secured, and the timing or terms of potential deals could impact commercial momentum. Regulatory outcomes, including the possibility of an FDA advisory committee, add further uncertainty. Legacy product declines continue, and if Anafilm’s uptake is slower than expected, the company’s path to profitability could be delayed.

Forward Outlook

For Q3 2025, Aquestive guided to:

• Continued pre-commercial spending for Anafilm, focused on payer engagement and awareness-building.
• Steady manufacturing and supply revenue, with international growth offsetting Suboxone decline.

For full-year 2025, management maintained guidance:

• Total revenue of $44 million to $50 million
• Non-GAAP adjusted EBITDA loss of $47 million to $51 million

Management highlighted several factors that will shape the next six months:

• FDA feedback on the need for an advisory committee and progress toward the January 2026 action date
• Securing launch financing and finalizing commercial infrastructure

Takeaways

Aquestive is entering a critical period, with Anafilm’s FDA decision and commercialization readiness set to define its long-term value proposition.

• Launch Execution Will Drive Value: Success hinges on payer access, patient uptake, and speed to market post-approval.
• Financing and Coverage Are Key Swing Factors: Investors should monitor updates on funding and payer negotiations for signals on launch scalability.
• Watch for Regulatory Milestones: FDA advisory committee decisions and international regulatory filings will inform the global Anafilm opportunity.

Conclusion

Aquestive’s Q2 2025 results reflect a business in transition, with heavy investment in Anafilm’s launch and a clear focus on overcoming payer and financing hurdles. The next two quarters will be decisive as the company prepares for FDA action and commercial execution in a competitive, evolving market.

Industry Read-Through

The payer access headwinds highlighted by Aquestive echo a broader trend in specialty pharma, where even innovative therapies face significant reimbursement friction and rising patient out-of-pocket costs. Competitors in the rescue and specialty drug markets should expect similar delays in coverage and must plan for robust patient access infrastructure. The shift toward non-injectable, patient-friendly formulations is accelerating, but real-world uptake will be dictated by both clinical differentiation and the ability to navigate complex payer landscapes. Manufacturers with U.S.-based supply chains may also enjoy near-term stability amidst ongoing tariff volatility.

AQST Healthcare Specialty Pharma Drug Launch Payer Access FDA Oral Film Commercialization